John Crowley, Chairman & CEO of Amicus Therapeutics, Inc. and FDA Commissioner Margaret Hamburg will deliver Keynote Addresses

• Godfrey Amphlett, Ph.D., Vice President, Process and Analytical Development, Immunogen
• Mohan Bala, Ph.D., Head, Oncology Market Access, Sanofi
• Detlev Biniszkiewicz, PhD, Vice President, Oncology Innovative Medicines Unit, AstraZeneca
• Bruce Booth, PhD, Partner, Atlas Ventures
• Samantha Budd, Vice President, Neuroscience iMed, AstraZeneca
• William Chin, MD, Executive Dean for Research, Bertarelli Professor of Translational Medical Science, Harvard Medical School
• Keting Chu, MD, PhD, Vice President, Research TAP, Leukemia & Lymphoma Society
• Robert K. Coughlin, President & CEO, MassBio
• John Crowley, Chairman and CEO, Amicus Therapeutics, Inc.
• Elan Ezickson, Executive Vice President and Chief Operating Officer, Aveo Oncology
• Claire Fisher, Business Development and Strategy, Blueprint Medicines
• Jeff Elton, PhD, Managing Director in Life Sciences, Accenture
• Chris Garabedian, President and CEO, Sarepta Therapeutics
• Steven C. Gilman, PhD, Executive Vice President, R&D and Chief Scientific Officer, Cubist Pharmaceuticals
• Sandra Glucksmann, PhD, Senior Vice President of Research and Development, Cerulean Pharma Inc.
• Gino Grampp, Regulatory Director, Amgen
• Margaret Hamburg, Commissioner, FDA
• Kris Joshi, PhD, Global Vice President - Healthcare, Health Sciences Global Business Unit, Oracle Corporation
• Kenneth Kaitin, PhD, Director and Research Professor, Tufts Center for the Study of Drug Development
• Camille Nelson Kotton, MD, Clinical Director, Transplant and Immunocompromised Host Infections Diseases, Infections Diseases Division, Massachusetts General Hospital
• Kevin Krenitsky, MD, Chief Commercial Officer and Senior Vice President, International Business Strategy, Foundation Medicine
• Art Krieg, MD, CEO, RaNA Therapeutics
• Raju Kucherlapati, PhD, Department of Genetics, Harvard Medical School
• Andy Lee, Senior Vice President, Head Global Clinical Operations, Genzyme Corporation
• Reid Leonard, PhD, Managing Director, Merck Research Ventures Fund, Merck
• Mark Leuchtenberger, President and CEO, Rib-X
• Mark Levin, Partner, Third Rock Ventures
• Jeffrey Luber, JD, Vice President and Co-Founder, SynapDx
• Timothy B. Lowinger, PhD., Chief Scientific Officer, Mersana Therapeutics, Inc.
• Geoff Mackay, Chariman of the Board, MassBio; President and CEO, Organogenesis
• David Meeker, MD, President and CEO, Genzyme Corporation 
• Rachel Meyers, PhD, Vice President, Research and RNAi Lead Development, Alnylam Pharmaceuticals
• Alan Moses, MD, Senior Vice President and Global Chief Medical Officer, Novo Nordisk
• Elizabeth Nabel, MD, President, Brigham and Women's Healthcare
• Sridaran Natesan, PhD, Vice President for External Innovation, Sanofi
• Claude Nicaise, MD, Senior Vice President of Strategic Product Development and Global Regulatory Affairs, Alexion Pharmaceuticals, Inc.
• Torben Straight Nissen, PhD, Managing Director, Centers for Therapeutics Innovation, Pfizer
• Bernat Olle, PhD, Principal, PureTech Ventures
• Dr. Mark Poznansky, MD, PhD, MGH
• Sam Rasty, PhD, Vice President, New Products, Shire HGT
• Bernard Ravina, MD, Medical Director, Translational Neurology, Biogen Idec.
• Jim Roach, MD, SVP, Development and Chief Medical Officer, Momenta Pharmaceuticals
• Reisa Sperling, MD, Director, Center for Alzheimer Research and Treatment, Harvard Medical School
• Lioudmila Tchistiakova, PhD, Senior Director, Global Biotherapeutic Technologies, Pfizer BioTx
• David L. Van Brunt, PhD, Director, Health Economics and Outcomes Research, Biogen Idec
• Jeffrey Voss, PhD, Senior Principal Research Scientist/Associate Director, AbbVie Pharmaceuticals
• Lujing Wang, MD, MPH, Managing Director, Commercial Center of Excellence, Campbell Alliance
• Lisa Whittemore, Vice President, Network Performance Imrpovement, Blue Cross Blue Shield of Massachusetts
• Janet Wolfe, PhD, President and Chief Executive Officer, Wolfe Laboratories
• Y. Katherine Xu, PhD, Senior Research Analyst, Biotechnology at William Blair & Co.
• Paul Young, PhD, U.S. Head, External Innovation, EMD Serono, Inc.